Absorption
|
| Process of taking in; chemicals can be absorbed into the bloodstream after breathing or swallowing. |
ADMET
|
| Investigation of Absorption Distribution Metabolism Excretion and Toxicology. |
Adverse effect
|
| Undesirable and unintended, although not necessarily unexpected, result of therapy or other treatment. |
Agonist
|
| Drug that binds cellular receptors which are ordinarily stimulated by naturally occurring substances, triggering a response. |
Amino acid
|
| Any of a class of 20 molecules that are combined to form proteins in living organisms. |
Amino acid sequence
|
| Linear order of the amino acids in a protein or peptide. |
Amplification
|
| "Increase in the number of copies of a specific DNA fragment; can be in vivo or in vitro. See cloning, polymerase chain reaction." |
Antagonist
|
| Compound that binds a receptor without triggering a response. |
Antibiotics
|
| Drugs that fight infection by killing bacteria and other micro-organisms. |
Antibody
|
| Protein produced by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind only to a specific antigen. |
Antigen
|
| Any foreign or non-self substance that causes the immune system to create an antibody. |
Anti-infective
|
| Drug used to treat infections caused by bacteria, protozoa, and other micro-organisms. |
Assay
|
| Any combination of targets and compounds which is exposed to a detection device to measure chemical or biological activity. |
Beads
|
| Small spheres (a few micrometers in diameter) made of polysterene or other polymers used as solid carrier material for chemical synthesis of compounds |
Biochemical assay
|
| Assay run on targets without cells. |
Cell
|
| Smallest membrane-bound biological unit capable of replication. |
Cell membrane
|
| The phospholipid bilayer that surrounds a cell, forming a selectively permeable barrier. |
Cellular assay
|
| Assay run on whole living cells. |
Chromatography
|
| Separation of a mixture by flowing it through or around stationary materials which selectively delay or adsorb components of the mixture. |
Chromosome
|
| "Single DNA molecule; the DNA-bearing structure that carries the inheritable characteristics of an organism." |
Clinical trials
|
| Research studies that involve humans. |
Clone
|
| Group of identical genes, cells, or organisms derived from a single ancestor. |
Cloned DNA
|
| Any DNA fragment that passively replicates in the host organism after it has been joined to a cloning vector. |
Cloning
|
| Process of making genetically identical copies. |
Cloning vector
|
| Molecular vehicle for introducing and replicating recombinant DNA in host organisms. |
Combinatorial chemistry
|
| Chemical synthesis that creates large numbers of organic compounds by putting chemical 'building blocks' together in every possible combination. |
CoMFA
|
| Comparative molecular field analysis; a 3D QSAR method developed by Tripos which uses PLS statistics and electrostatic/steric fields. |
Compound
|
| Substance made up of two or more elements that cannot be separated. |
Diffusion
|
| Molecular movement from areas of high concentration to areas of low concentration. |
Deoxyribonucleic acid (DNA)
|
| carrier of genetic information and blueprint of proteins. |
DNA
|
| See Deoxyribonucleic acid |
Docking
|
| Computer simulation of the binding interaction of a small molecule compound with a protein structure. |
Drug
|
| Any chemical compound that may be used on humans to help in diagnosis, treatment, cure, mitigation, or prevention of disease or other abnormal conditions. |
E. coli
|
| Common non-pathogenic bacterium; easy to grow in the laboratory, often used as host cells. |
Enzyme
|
| Protein that acts as a catalyst, affecting the rate at which chemical reactions occur in cells. |
False negative
|
| When a test wrongly shows an effect or condition to be absent. |
False positive
|
| When a test wrongly shows an effect or condition to be present. |
Femto
|
| Amount of 1x10-15 |
Fermenter
|
| Bioreactor used to manufacture or modify products (compounds) with help of micro-organisms. |
Fluorescence
|
| Process whereby colours (dyes) absorb radiant power at one wavelength and immediately re-emit it at another (usually longer) wavelength. |
Fluorescence lifetime
|
| Average time that a population of fluorophores spends in the excited state before collapse to the ground state. |
Fluorescence polarization
|
| Measure of the mobility of a fluorophore: A mobile fluorophore is able to reorient itself within its fluorescence lifetime and therefore emits unpolarized light; an immobile fluorophore does not reorient and hence emits light polarized in the plane of exc. |
Fluorophore
|
| Optically active part of a fluorescent dye molecule. |
Gene
|
| "Unit of inheritance; a working subunit of DNA containing the code for a specific product, typically, a protein such as an enzyme." |
Gene expression
|
| Process by which a genes coded information is translated into the structures present and operating in the cell (either proteins or RNAs). |
Gene markers
|
| Landmarks for a target gene, either detectable traits that are inherited along with the gene, or distinctive segments of DNA. |
Gene product
|
| Biochemical material, either RNA or protein, resulting from expression of a gene. |
Generic assay
|
| Assay formulations of identical composition with respect to the target. |
Genetics
|
| Scientific study of heredity how particular qualities or traits are transmitted from parents to offspring. |
Genome
|
| All the genetic material in the chromosomes of a particular organism; its size is generally given as its total number of base pairs. |
Genome projects
|
| Research and technology development efforts aimed at mapping and sequencing some or all of the genome of human beings and other organisms. |
Genomics
|
| Identification and functional characterization of genes. |
Genotype
|
| Genetic constitution of an organism. |
High Performance Liquid Chromatography (HPLC)
|
| Chromatography method with very high degree of resolution using high pressures to force the mixture to be separated to pass through a column containing the separating resin. |
High Throughput Screening (HTS)
|
| Technique of rapidly searching for molecules with desired biological effects from very large compound libraries. |
Hit
|
| Compound found by screening to have a significant biological effect e.g. IC50 < 10 µM. |
Homogeneous assay
|
| Assay which does not require any chemical modification or purification steps after the reaction has started. |
HPLC
|
| See High Performance Liquid Chromatography |
HTS
|
| See High Throughput Screening |
Human Genome Project
|
| International research effort aimed at mapping and sequencing all of the genome of the human species. |
Hybridization
|
| Process of joining two complementary strands of DNA or one each of DNA and RNA to form a double-stranded molecule. |
In vitro
|
| In a test tube. |
In vivo
|
| In the living organism as opposed to in vitro. |
IND
|
| Investigational new drug; application must be approved by the Food and Drug Administration (FDA) before a drug can be tested in humans in clinical trials. |
Ion channel
|
| Protein which allows the passage of ions across cell membranes. |
Lead
|
| Substance that is chosen for experimental evaluation on the basis of its predicted qualities and its likelihood of leading to a drug discovery. |
Library
|
| Collection of a multitude of different molecules for screening. |
Ligand
|
| Chemical compound, usually released by one cell to communicate with a different cell by binding to specific receptors on the receiving cells surface. |
Liquid handling
|
| Pipetting, pumping and dispensing of volumes of liquid. |
Metabolism
|
| All the chemical reactions in an organism that enable the organism to live. |
Messenger RNA (mRNA)
|
| RNA that serves as a template for protein synthesis. |
Molar
|
| 1 mole of a compound per liter solvent. Mole is used in chemistry to express a number of molecules (6,623x1023). |
mRNA
|
| See Messenger RNA |
Micro
|
| Amount of 1 x 10-6 |
Micro-organisms
|
| Single-cell organisms, for example bacteria and fungi, but not viruses. |
Nano
|
| Amount of 1 x 10-9 |
Nanomolar
|
| Concentration of 1 x 10-9 mole per liter. |
Nucleus
|
| The organelle that houses the chromosomes. |
Organisms
|
| Plants, animals, and other forms of life that are made up of complex and interconnected systems of cells and tissue. |
Orphan receptor
|
| Receptor with unknown function binding known ligands. |
Pathogen
|
| Agent that causes disease, especially a micro-organism. |
PCR
|
| See Polymerase chain reaction |
Peptide
|
| Molecule consisting of 2 to approximately 20 amino acids; a short segment of a larger protein or a completely functional molecule unto itself. |
Pharmacokinetics
|
| Movements of drugs within biological systems, as affected by absorption, distribution, metabolism, excretion (ADME). |
Phase I
|
| Closely monitored clinical trial of a drug or vaccine conducted in a small number of healthy volunteers; used to determine toxicity, pharmacokinetics, preferred route of administration, and safe dosage range of a drug. |
Phase II
|
| Controlled clinical study of a drug or vaccine to identify common shortterm side effects and risks associated with the drug or vaccine, to collect information on its immunogenicity and to demonstrate its efficacy conducted on a limited number of patients |
Phase III
|
| Clinical studies involving a larger number of patients, designed to assess safety, effectiveness, and optimum dosage of a drug as administered in a treatment setting usually including several hundred to several thousand volunteers. |
Polymerase
|
| Any enzyme that catalyzes the formation of DNA or RNA from building blocks. |
Polymerase chain reaction (PCR)
|
| Method for amplifying (exponentially copying) a DNA molecule in vitro. |
Protease
|
| Any enzyme that catalyzes the cleavage of a peptide or protein. |
Protease inhibitors
|
| Class of drugs designed to inhibit the enzyme protease. |
Protein
|
| Large, complex molecule composed of amino acids. Proteins are essential to the structure, function, and regulation of the body. Examples are hormones, enzymes, and antibodies. |
Proteome
|
| Complete profile of all expressed (produced) proteins within a cell, a tissue, or an entire organism at a given time. |
Proteomics
|
| Analysis of the functions and interactions of proteins in healthy tissue compared to tissue affected by a disease. |
QSAR
|
| Quantitative structure activity relationship, statistical method of investigating three dimensional properties and biological activities of sets of molecules. |
Reagent
|
| Any chemical used in a laboratory test or experiment. |
Receptor
|
| Protein in a cell or on its surface that selectively binds a specific substance (ligand). Upon binding its ligand, the receptor triggers a specific response in the cell. |
Recombinant DNA molecules
|
| Combination of DNA molecules of different origin that are joined using recombinant DNA technologies. |
Recombinant DNA technologies
|
| Procedures used to join together DNA segments in vitro. |
RNA
|
| Ribonucleic acid: form of genetic information; takes part in translation of DNA into proteins. |
Screening
|
| Application of an established assay format to compound libraries in mass testing. |
Sequencing
|
| Process by which the order and identity of the molecular building blocks that comprise a DNA or protein molecule is determined. |
Side effect
|
| See adverse effect. |
Substrate
|
| Chemical compound that is recognized and modified by an enzyme. |
Subtractive analysis
|
| Description of a situation by finding the difference between two states, for example between healthy cells and the same cells affected by a disease. |
Syndrome
|
| Recognizable pattern or group of multiple signs, symptoms or malformations that characterize a particular condition. |
Target
|
| Specific biological molecule, such as an enzyme, receptor or ion channel, assumed to be relevant to a certain disease. Most drugs work by binding to a target, thereby affecting its biological function. |
Target identification
|
| Identifying a molecule (often a protein) that is instrumental to a disease process (though not necessarily directly involved), with the intention of finding a way to regulate that molecules activity for therapeutic purposes. |
Target validation
|
| Crucial step in the drug discovery process. Following the identification of a potential disease target, target validation verifies that a drug that specifically acts on the target can have a significant therapeutic benefit in the treatment of a given dise |
Toxicology
|
| Scientific discipline concerned with understanding the mechanisms by which chemicals produce noxious effects on living tissues or organisms. |
Translational diffusion
|
| Diffusion-induced movement of a molecule or particle along all three axes within a three-dimensional space. |
vHTS
|
| See virtual High Throughput Screening |
virtual High Throughput Screening (vHTS)
|
| Computer simulated screening of huge databases of molecules. |
Virtual library
|
| Database of a multitude of different molecules for virtual screening. |
Virus
|
| Infectious biological particle composed of a piece of genetic material RNA or DNA surrounded by a protein coat. |